Mobile

An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed o...

Update Il y a 4 ans
Reference: EUCTR2016-002036-32

An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate efficacy, as measured by best objective response rate (ORR)

Inclusion criteria

  • Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

Links